asco 2021: latest on parpi and other treatments for mcrpc
Published 3 years ago • 104 plays • Length 17:44Download video MP4
Download video MP3
Similar videos
-
1:39
challenges in the field of parpi treatment for mcrpc
-
18:13
asco 2021: precision and molecular reporting for prostate cancer
-
6:41
esmo expert report on combination therapy in advanced prostate cancer @ asco gu 2022
-
27:02
mcrpc: latest developments in diagnostics and combination therapies
-
6:46
what is provenge? learn about immunotherapy for prostate cancer
-
8:39
#olaparib | uses, dosage, side effects & mechanism | lynparza
-
3:39
dna damage response
-
35:58
esmo 2021: parpi data and their role in mono/combination therapies
-
14:58
asco 2018: novel treatment strategies in prostate cancer therapeutics
-
5:06
va starport prostate cancer clinical trial
-
38:47
parp inhibitors and their evolving role for the treatment of prostate cancer
-
1:23
the evolving treatment landscape of mhspc and mcrpc
-
46:50
mcrpc and nmcrpc: combinations and latest data, what does covid mean for early treatment?
-
11:51
expert video report on castration sensitive and resistant prostate cancer - 2021 asco annual meeting
-
39:02
systemic therapies for the treatment of advanced prostate cancer
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer
-
21:15
parpi in pc - case based testing and clinical decisions
-
2:16
testing the validity of a prognostic model for castration-resistant prostate cancer
-
18:54
asco 2018: latest developments in non-metastatic & metastatic castration-resistant prostate cancer
-
53:17
targeting advanced prostate cancer with parp inhibitors: who, when and how?
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer